JPS58134032A - 制癌性製剤 - Google Patents
制癌性製剤Info
- Publication number
- JPS58134032A JPS58134032A JP57015574A JP1557482A JPS58134032A JP S58134032 A JPS58134032 A JP S58134032A JP 57015574 A JP57015574 A JP 57015574A JP 1557482 A JP1557482 A JP 1557482A JP S58134032 A JPS58134032 A JP S58134032A
- Authority
- JP
- Japan
- Prior art keywords
- anticancer
- liposomes
- cancer
- liposome
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001093 anti-cancer Effects 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title description 3
- 239000002502 liposome Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002842 anticancer formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZLXYMQOCNYUIO-UHFFFAOYSA-N lithium;hydrochloride Chemical compound [Li].Cl PZLXYMQOCNYUIO-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57015574A JPS58134032A (ja) | 1982-02-04 | 1982-02-04 | 制癌性製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57015574A JPS58134032A (ja) | 1982-02-04 | 1982-02-04 | 制癌性製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58134032A true JPS58134032A (ja) | 1983-08-10 |
| JPH0355450B2 JPH0355450B2 (https=) | 1991-08-23 |
Family
ID=11892499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57015574A Granted JPS58134032A (ja) | 1982-02-04 | 1982-02-04 | 制癌性製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58134032A (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63503113A (ja) * | 1986-04-23 | 1988-11-17 | ニューヨーク ユニバーシィティ | 接触一抑制性因子の製造法 |
| JPH01113319A (ja) * | 1987-10-27 | 1989-05-02 | Nippon Oil & Fats Co Ltd | リポソームカプセル化したマクロファージ活性化剤 |
| US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| KR20030075213A (ko) * | 2002-03-16 | 2003-09-26 | (주)케비젠 | 항암물질을 함유하는 수용성 필름제 및 이의 제조방법 |
| US7311912B1 (en) | 1997-01-10 | 2007-12-25 | Plantbodies Corporation | Epithelial tissue targeting agent |
| WO2020241830A1 (ja) | 2019-05-29 | 2020-12-03 | 学校法人早稲田大学 | 生体分子の検出のための温度応答性蛍光粒子 |
-
1982
- 1982-02-04 JP JP57015574A patent/JPS58134032A/ja active Granted
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63503113A (ja) * | 1986-04-23 | 1988-11-17 | ニューヨーク ユニバーシィティ | 接触一抑制性因子の製造法 |
| JPH01113319A (ja) * | 1987-10-27 | 1989-05-02 | Nippon Oil & Fats Co Ltd | リポソームカプセル化したマクロファージ活性化剤 |
| US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| US6391280B1 (en) | 1997-01-10 | 2002-05-21 | Epicyte Pharmaceutical, Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| US7022309B2 (en) | 1997-01-10 | 2006-04-04 | Biolex Newco I, Inc. | Targeting molecule linked to an imaging agent |
| US7311912B1 (en) | 1997-01-10 | 2007-12-25 | Plantbodies Corporation | Epithelial tissue targeting agent |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| US6440419B1 (en) | 1997-10-20 | 2002-08-27 | Epicyte Pharmaceutical, Inc. | Epithelial cell targeting agent |
| KR20030075213A (ko) * | 2002-03-16 | 2003-09-26 | (주)케비젠 | 항암물질을 함유하는 수용성 필름제 및 이의 제조방법 |
| WO2020241830A1 (ja) | 2019-05-29 | 2020-12-03 | 学校法人早稲田大学 | 生体分子の検出のための温度応答性蛍光粒子 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0355450B2 (https=) | 1991-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI86077C (fi) | Monoklonala antikroppar och metod att producera dessa. | |
| US5837845A (en) | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane | |
| EP0871673B1 (en) | Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety | |
| JPH04346918A (ja) | 薬剤含有タンパク質結合リポソーム | |
| Tsutsumi et al. | Immunohistochemical observations of carcinoembryonic antigen (CEA) and CEA-related substances in normal and neoplastic pancreas: Pitfalls and caveats in CEA immunohistochemistry | |
| JPS61227532A (ja) | 抗体ハイブリツド分子およびその製造方法 | |
| PT89385A (pt) | Processo para a preparacao de novos anticorpos | |
| JPS58208238A (ja) | 共有結合によつて酵素と抗体を結合させる新しい共役物とこの共役物を用いた医薬会合 | |
| EP0614486A1 (en) | Targeted delivery of virus vector to mammalian cells | |
| JPH0759518B2 (ja) | 自己由来のワクチン | |
| JP2022087135A (ja) | 複数細胞標的化リポソーム | |
| JPS58134032A (ja) | 制癌性製剤 | |
| CA2387383C (fr) | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers | |
| Gregoriadis et al. | Interaction of antibody-bearing small unilamellar liposomes with target free antigen in vitro and in vivo. Some influencing factors | |
| JP3223159B2 (ja) | モノクローナル抗体の製造方法 | |
| JPH01168299A (ja) | モノクローナル抗体およびそれを産生するハイブリドーマ | |
| Samaan et al. | Ectopic parathyroid hormone production by a squamous carcinoma of the tonsil | |
| JP3123056B2 (ja) | 合成糖脂質特異性モノクローナル抗体 | |
| JPH022394A (ja) | アンスラサイクリン化合物に対するモノクロナール抗体 | |
| FR2543971A1 (fr) | Anticorps contre le cancer humain de la vessie | |
| JPH0276899A (ja) | 双特異性抗体の製造法 | |
| JPH0433935A (ja) | ロドプシン薄膜とその作製方法 | |
| CA1329545C (en) | Immunological complex, its preparation and its use | |
| JPH0347090A (ja) | 二重特異性を有するハイブリッドモノクローナル抗体 | |
| JP2004091454A (ja) | 抗体及びその製造方法並びに抗体を用いた抗原の定量方法 |